BRCA1 and ovarian carcinoma: Olaparib is a novel PARP inhibitor with increased specificity for PARP-1 and -224 that was approved for the treatment of ovarian cancer positive for BRCA1/2 mutations (FDA reference ID: 3675412) in 2014.